On August 27, 2026 Affibody AB ("Affibody"), a clinical stage radiopharmaceutical company developing next generation Radioligand Therapies (RLTs), reported participation in two upcoming investor conferences, delivering an update on clinical data from the ongoing Phase 1 study evaluating the RLT candidate, ABY-271, in patients with HER2-positive metastatic breast cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Morgan Stanley 24th Annual Global Healthcare Conference (New York City)
Presentation and 1×1 Investor Meetings
Tuesday, September 15
4th Annual Oppenheimer Targeted Radiopharmaceutical Therapies Summit (New York City)
1×1 Investor Meetings
Thursday, September 17
(Press release, Affibody, AUG 27, 2026, View Source [SID1234670383])